When you use the GLP-1 cost guide to compare quotes, check what you would owe after coverage and what the same prescription would cost at renewal. In one supervised weight program, out-of-pocket cost was the main reason people declined liraglutide [1]. The study did not establish a refusal rate across all GLP-1 prescriptions.
Who was offered liraglutide
The 12-week program enrolled 174 adults with obesity. At week six, the researchers offered liraglutide to the 78 participants who had lost less than 2.5% of their starting weight. Twenty-one agreed to start and 57 declined.
Over the next six weeks, those who started lost an average of 3.5 kg (3.2%), compared with 1.3 kg (1.4%) among those who declined (P<0.001). Four participants reported nausea and two reported upper abdominal pain.
What national data say about access
A separate analysis of U.S. Medical Expenditure Panel Survey data from 2017 to 2023 measured use of GLP-1 receptor agonists and SGLT2 inhibitors together [2]. If coverage is uncertain, the insurance worksheet helps you check the formulary and record any approval requirements. The survey measured medication use across both drug classes and cannot tell you how often people turned down a GLP-1 prescription.
What Swedish doctors reported
A 2024 survey in five Swedish regions received 190 responses, a response rate of 28%, and analyzed 163 [3]. During that survey, 86% identified supply shortages and 69% identified high patient copayments as prescribing barriers. The figures describe the responding doctors during that period.
Starting and staying on treatment
The research on why people stop taking a GLP-1 examines patients who had already begun treatment. The liraglutide study captured an earlier decision, when participants were first offered the prescription.